Neos Therapeutics (NASDAQ:NEOS) soared in morning trading after the company’s drug to treat a common type of childhood behavioral disorder was approved by the U.S. Food and Drug Administration.
The drug, Adzenys XR-ODT, is approved for the treatment of Attention Deficit Hyperactivity Disorder (ADHD) in patients aged six and older, the Texas-based company said in a statement on Thursday.
16:36 AT&T, Time Warner poised to lobby lawmakers, regulators on proposed $85-billion merger24
12:23 Lockheed Martin's quarterly profit handily beats estimates28
11:41 Caterpillar earnings: 85 cents per share, vs expected EPS of 76 cents23
00:02 AT&T Aims for an Empire in Merger Talks With Time Warner13